Core Insights - IQVIA Holdings Inc reported a fourth adjusted EPS of $3.12, an increase from $2.84, surpassing the consensus of $3.11 [1] - The company achieved sales of $3.96 billion, nearly matching the consensus of $3.94 billion, with a revenue increase of 2.3% on a reported basis and 3.0% at constant currency [1] - The Technology & Analytics Solutions (TAS) segment generated revenue of $1.66 billion, reflecting an 8.3% growth on a reported basis and 9.5% at constant currency [1] Revenue Breakdown - Research & Development Solutions (R&DS) revenue was $2.123 billion, showing a decrease of 1.3% on a reported basis and 1.0% at constant currency [2] - The R&DS contracted backlog, including reimbursed expenses, reached $31.1 billion, growing 4.4% year-over-year and 5.5% at constant currency [2] - Approximately $7.9 billion of the backlog is expected to convert to revenue in the next twelve months, with a fourth-quarter book-to-bill ratio of 1.20x [2] Management Commentary - The CEO of IQVIA stated that the company delivered excellent fourth-quarter performance and that R&DS revenue was on target, with bookings exceeding expectations despite a challenging CRO market [2] - The TAS segment showed strong momentum, suggesting that the company's growth target for 2025 may be conservative [4] Guidance and Outlook - IQVIA reaffirms its 2025 sales outlook of $15.725 billion to $16.125 billion, compared to a consensus of $16.03 billion [2] - The company anticipates adjusted EPS of $11.70-$12.10, against a consensus of $11.88, and adjusted EBITDA of $3.765 billion to $3.885 billion [3] - Stronger-than-expected bookings in the R&DS segment enhance confidence in achieving mid-single-digit revenue growth for 2025, excluding COVID-related revenue [3] Market Reaction - Following the earnings report, IQV stock increased by 2.8%, reaching $211.36 [4]

IQVIA Holdings (IQV) reported $3.96 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 2.3%. EPS of $3.12 for the same period compares to $2.84 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.92 billion, representing a surprise of +0.89%. The company delivered an EPS surprise of +0.65%, with the consensus EPS estimate being $3.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Core Insights - IQVIA Holdings reported quarterly earnings of $3.12 per share, exceeding the Zacks Consensus Estimate of $3.10 per share, and up from $2.84 per share a year ago, indicating a 9.86% year-over-year increase [1] - The company achieved revenues of $3.96 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.89% and showing a year-over-year increase from $3.87 billion [2] - IQVIA has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] Earnings Outlook - The sustainability of IQVIA's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - Current consensus EPS estimate for the upcoming quarter is $2.59 on revenues of $3.85 billion, while for the current fiscal year, the estimate is $11.80 on revenues of $16.02 billion [7] Industry Context - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Exhibit 99.1 IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance RESEARCH TRIANGLE PARK, N.C. February 6, 2025 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024. "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari ...

IQVIA Holdings Inc. (IQV) will release its fourth-quarter 2024 results on Feb. 6, before market open.See Zacks Earnings Calendar to stay ahead of market-making news.IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.7%.IQVIA Holdings Inc. Price, Consensus and EPS Surprise IQVIA’s Q4 ExpectationsThe Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 1.4% growth from the year-ago quar ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

The upcoming report from IQVIA Holdings (IQV) is expected to reveal quarterly earnings of $3.11 per share, indicating an increase of 9.5% compared to the year-ago period. Analysts forecast revenues of $3.92 billion, representing an increase of 1.4% year over year.The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior t ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? IQVIA Holdings (IQV) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.This clinical testing company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 1.70%.For the most recent quarter, IQVIA was ...

IQVIA Holdings Inc. (IQV) is benefiting from its ability to standardize, organize and integrate data through analytics and global technology, which boosts its client base. Shareholder-friendly policy is another green flag for investors. Meanwhile, competitive pressure is troublesome and low liquidity poses a threat to the company’s ability to pay off short-term debt.IQV reported impressive third-quarter 2024 results. Adjusted earnings were $2.8 per share, outpacing the Zacks Consensus Estimate by 1.1% and r ...